OPT

6.43%

65.5¢ opthea limited

A few more slides in the presentation (I think) at JP Morgan...

First 6 Last

Share
Profile

Follow
gmutton

2,505 Posts.

10

25/01/17

15:40

Post #: 22137497
Share

Originally posted by yehudi ↑

Bioshares provided an update on Opthea this week. Nothing particularly new.
Here is a brief summary. Megan Baldwin attended meetings earlier this month around the JP Morgan Healthcare Conference in San Francisco. She took the opportunity to meet with potential pharmaceutical partners and investors. Baldwin said it was a really great meeting for the company. There was increased interest this year in Opthea from investors for two reasons. The first is that Opthea has advanced into clinical studies with its lead drug candidate OPT-302 for the treatment of wet AMD. Opthea has released positive Phase I- study data from 20 patients with data from an additional 31 patients in a Phase IIa study due to be released in Q1 this year. The results from the Phase I/IIa study out this quarter will have data on 51 patients, which should give reasonable information around both safety and efficacy. Another driver of investor interest in the US has been due to the setback experienced last year from a competing drug candidate Fovista from Ophthotech Corporation. Ophthotech's drug, Fovista, failed in two Phase III studies in AMD, combining Fovista with Lucentis. That result puts a serious question mark over the approach of blocking the PGDF pathway in treating wet AMD, which works strongly in Opthea's favour. Baldwin said that meetings with corporates (potential biotech/ pharmaceutical partners) was with those already on its list, with the meeting an opportunity to maintain dialogue and update on progress. Opthea expects to move into Phase IIb studies in the second half of this year. Results from the Phase IIa study will be used to inform the design of the Phase IIb trial (with respect to study size and achieving statistically significant outcomes). While the regulatory standard is to focus on treatment naïve patients, the company may also seek to build data around combination treatment of patients who have previously been treated with VEGF-A inhibitor therapy (Lucentis or Eylea). Baldwin said that the Phase IIb study will be statistically powered and will be conducted to a globally relevant standard that will see the trial and the company recognised internationally. The Phase IIb study will be conducted in the US and Europe, and potentially Australia. Opthea is funded to conduct a “good sized” study according to Baldwin.

Perhaps the last comment leaves the door slightly ajar in terms of if a larger study was to be looked at then a capital rising would be required

Expand

A few more slides in the presentation (I think) at JP Morgan conference.
From the website

http://www.opthea.com/pub/pdf/ASXAnnouncements/ASX_OPT_JPM 2017_CorporatePresentation.pdf

OPT Price at posting: 86.5¢ Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

BNL

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

EDE

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

AN1

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

AUN

Cyclone signs MOU with Vale for development of Iron Bear play

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

GRL

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

ME1

Banshee's historic trenches prove rich in antimony and gold for GDM

LYN

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

HotCopper Highlights: Your most watched stocks for Week 46, 2024

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

There are more pages in this discussion • 11 more messages in this thread...

First 6 Last

Add OPT (ASX) to my watchlist

(20min delay)
Last 65.5¢		Change -0.045(6.43%)		Mkt cap ! $855.6M

Open	High	Low	Value	Volume
69.5¢	69.5¢	63.0¢	$2.808M	4.305M

Buyers (Bids)

No.	Vol.	Price($)
1	49996	65.5¢

Sellers (Offers)

Price($)	Vol.	No.
66.0¢	50869	6

View Market Depth

No.	Vol.	Price($)
4	45916	0.590
2	37273	0.585
3	38706	0.580
2	108695	0.575
3	44061	0.570

Price($)	Vol.	No.
0.600	10000	1
0.605	47182	2
0.610	42308	4
0.615	1600	1
0.620	130700	4

Last trade - 16.10pm 15/11/2024 (20 minute delay)

OPT (ASX) Chart

A few more slides in the presentation (I think) at JP Morgan...

Top Stories

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

Cyclone signs MOU with Vale for development of Iron Bear play

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Banshee's historic trenches prove rich in antimony and gold for GDM

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

HotCopper Highlights: Your most watched stocks for Week 46, 2024

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

Buyers (Bids)

Sellers (Offers)